The prevalence of human papillomavirus (HPV) is rising among individuals in both developed and developing countries, imparting a massive boost to the global market for HPV therapeutics, says Transparency Market Research. The business intelligence firm projects that the global HPV therapeutics market, which approximated US$1.40 bn in 2012, will exhibit a strong CAGR of 7.7% between 2014 and 2020 and stand at US$2.34 bn by 2020.
The report that states these findings also includes a comprehensive study on the global cytomegalovirus therapeutics market. According to TMR, the global CMV therapeutics market had a valuation of US$870.1 mn in 2012 and will stand at US$922.8 mn by 2020 at a 1.49 % CAGR from 2014 through 2020.These findings are discussed in detail in the report, titled “Human Papillomavirus Therapeutics Market – Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020.”
According to the report, researchers have identified over 100 strains of HPV so far. Of these strains, a few are known to lead to papillomas or warts, which grow to develop into either malignant or benign cancers. Young adults and adolescents are at the highest risk of contracting HPV infections, and the highest prevalence of the same is seen among adolescent females. The CDC estimates that as of 2012, about 20 million Americans were infected by HPV. This has led to a high demand for therapies to treat both human papillomavirus and cytomegalovirus infections.
The HPV therapeutics market is composed of the following drug classes: immunomodulators, anti-neoplastic agents, sinecatechins, and keratolytic agents. Of these, the largest share of the HPV therapeutics market was held by immunomodulators. The fastest growth will be seen in the sinecatechins segment. Basis application, the majority of HPV therapeutics will be used to treat genital warts until 2020, the report finds. This segment will contribute to the highest share of revenue to the global HPV therapeutics market.
The HPV therapeutics market is expected to be imparted a blow from a relatively dry pipeline of drugs and the availability of various substitutes in the form of laser therapy and cryotherapy. This will decrease the attractiveness of the market during the report’s forecast period. From the regional perspective, the markets of South America and Asia Pacific will be most attractive to investors as the prevalence of STDs is increasing in these regions.
On the cytomegalovirus infections therapeutics market, the report states that symptomatic CMV infections mostly prevail in patients infected with HPV or those who have undergone a transplant. Basis antiviral drugs, the CMV therapeutics market can be segmented into ganciclovir/valganciclovir (first line drugs), cidofovir, and foscarnet. Of these, ganciclovir and valganciclovir together contribute over 85% of all revenue to the CMV therapeutics market globally.
CMV, owing to high seroprevalence of approximately 95% in middle- and low-income countries, threatens to infect a large portion of the population. This is compounded by the fact that many HIV patients are now showing resistance to ganciclovir and valganciclovir. The CMV therapeutics market could receive a boost with the slated launch of letermovir (2018) and brincidofovir (2016).
The companies that dominate the HPV therapeutics market and CMV therapeutics market, respectively, are Valeant Pharmaceuticals (70% of the market) and Roche AG (85% of the market).
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453